By Counterforce Health Team in Alecensa (alectinib) —

How to Get Alecensa (alectinib) Covered by UnitedHealthcare in Virginia: Complete PA Guide with Forms and Appeals

Answer Box: Getting Alecensa Covered by UnitedHealthcare in Virginia

Alecensa (alectinib) requires prior authorization from UnitedHealthcare and must be dispensed through a specialty pharmacy. The fastest path to approval: (1) Confirm ALK-positive NSCLC with FDA-approved testing, (2) Submit prior authorization through UHC Provider Portal with complete clinical documentation, and (3) Be prepared to address step therapy requirements (typically crizotinib first-line). First step today: Call UnitedHealthcare at 888-397-8129 to verify your specific formulary tier and PA requirements, then gather ALK test results and treatment history for your oncologist's submission.

Table of Contents

  1. Plan Types & Coverage Implications
  2. Formulary Status & Tier Placement
  3. Prior Authorization Requirements
  4. Step Therapy & Utilization Controls
  5. Specialty Pharmacy Setup
  6. Cost-Share Dynamics
  7. Submission Process & Forms
  8. Common Approval Patterns
  9. Appeals Process in Virginia
  10. FAQ

Plan Types & Coverage Implications

UnitedHealthcare offers several plan types in Virginia, each with different coverage rules for Alecensa:

Medicare Advantage Plans: Cover Alecensa under Medicare Part D formulary with standardized cost-sharing (typically 25-33% coinsurance for specialty drugs). Prior authorization follows Medicare guidelines, and appeals use the standardized Medicare process.

Commercial Insurance: Coverage varies by employer group or individual plan. Formulary placement and step therapy requirements may differ from Medicare Advantage. Cost-sharing ranges from 20-40% coinsurance depending on plan design.

Network Requirements: All UnitedHealthcare plans require in-network specialty pharmacies for Alecensa coverage. Out-of-network fills typically result in denial except in emergencies.

Formulary Status & Tier Placement

Alecensa is listed as a Tier 2 medication on the 2024 UnitedHealthcare OptumRx Premium Standard Formulary and classified as a specialty medication requiring prior authorization. This placement means:

  • Mid-range cost-sharing (less than Tier 3 non-preferred brands)
  • Specialty pharmacy dispensing required
  • Prior authorization mandatory before coverage begins
  • 12-month initial authorization period with reauthorization based on disease stability
Note: Formulary tiers can vary by specific employer group or state Medicaid contracts. Always verify your plan's specific formulary through the UnitedHealthcare member portal.

Prior Authorization Requirements

UnitedHealthcare requires comprehensive clinical documentation for Alecensa approval:

Required Clinical Criteria

Requirement Documentation Needed Where to Find
ALK-Positive Status FDA-approved ALK test results Pathology report with specific test method
NSCLC Diagnosis Confirmed non-small cell lung cancer Oncology notes, staging reports
Disease Status Advanced, metastatic, or recurrent disease Imaging studies, staging documentation
Prior Treatment History Previous therapies tried/failed or contraindications Treatment records, adverse event documentation

Submission Methods

Authorization Duration: Initial approvals are granted for 12 months. Reauthorization requires documentation that the patient shows no evidence of progressive disease.

Step Therapy & Utilization Controls

UnitedHealthcare typically requires patients to try crizotinib (Xalkori) before approving Alecensa for ALK-positive NSCLC, unless there's documented intolerance or contraindication.

Step Therapy Exceptions

You can bypass crizotinib if you document:

  • Intolerance or adverse reactions to crizotinib
  • Contraindications based on drug interactions or comorbidities
  • Clinical necessity for Alecensa as first-line therapy
  • Previous failure on crizotinib with documented progression
Clinician Tip: When requesting step therapy exceptions, include specific adverse events, drug interaction details, or clinical rationale citing current NCCN guidelines or FDA labeling.

Specialty Pharmacy Setup

Alecensa must be dispensed through UnitedHealthcare's approved specialty pharmacy network. Common network pharmacies include Accredo, Optum Specialty Pharmacy, and AllianceRx Walgreens Prime.

Patient Setup Process

  1. Prior Authorization Approval: Must be obtained before pharmacy setup
  2. Prescriber Service Form: Complete enrollment forms for specialty pharmacy
  3. Patient Consent: Sign consent forms for medication delivery and monitoring
  4. Insurance Verification: Specialty pharmacy confirms benefits and cost-sharing
  5. Home Delivery: Medication ships directly to patient's home address

Required Forms

  • Prescriber service enrollment form
  • Patient consent and delivery authorization
  • Financial assistance application (if applicable)

Coordination Note: Your oncology team should work directly with the specialty pharmacy to ensure seamless setup and delivery scheduling.

Cost-Share Dynamics

Medicare Advantage Plans

  • Specialty Drug Coinsurance: Typically 25-33% of drug cost
  • Out-of-Pocket Maximum: Federally regulated maximum for 2024
  • Coverage Gap: May apply until catastrophic coverage begins

Commercial Plans

  • Coinsurance Range: 20-40% depending on plan design
  • Deductible: May apply before coinsurance begins
  • Annual Maximum: Varies by employer group

Financial Assistance Options

  • Genentech Access Solutions: Manufacturer copay assistance for eligible patients
  • Independent Foundations: Cancer care foundations offering grant support
  • State Programs: Virginia may have additional assistance programs
Important: This is educational information only. Consult your plan documents for specific cost-sharing details.

Submission Process & Forms

Step-by-Step: Fastest Path to Approval

  1. Verify Coverage (Patient/Clinic): Call UnitedHealthcare member services to confirm plan benefits and formulary status
  2. Gather Documentation (Clinic): Collect ALK test results, staging reports, and prior treatment records
  3. Submit Prior Authorization (Prescriber): Use UHC Provider Portal with complete clinical documentation
  4. Specialty Pharmacy Setup (Clinic): Complete enrollment forms once PA is approved
  5. Monitor Status (Patient/Clinic): Track approval status through provider portal
  6. Appeal if Denied (Clinic/Patient): Submit internal appeal within required timeframes
  7. External Review (Patient): File with Virginia Bureau of Insurance if internal appeals fail

Key Documentation Checklist

  • ✓ ALK-positive test results with specific methodology
  • ✓ Complete staging and diagnosis documentation
  • ✓ Prior therapy history with outcomes
  • ✓ Current treatment plan and monitoring schedule
  • ✓ Prescriber attestation of medical necessity

Common Approval Patterns

Strong submissions typically include:

  • Comprehensive ALK Testing: Specific test method (IHC, FISH, NGS) with clear positive results
  • Treatment History: Detailed documentation of prior therapies, including dates, doses, and reasons for discontinuation
  • Clinical Narrative: Clear explanation of why Alecensa is medically necessary for this specific patient
  • Guideline Citations: References to NCCN guidelines or FDA labeling supporting the treatment choice

Common Denial Reasons & Solutions

Denial Reason Solution
Missing ALK test results Submit complete pathology report with FDA-approved test
Insufficient prior therapy documentation Provide detailed treatment history with outcomes
Step therapy not completed Document contraindications or request exception
Incomplete clinical information Submit comprehensive oncology notes and staging

Appeals Process in Virginia

If UnitedHealthcare denies your Alecensa request, Virginia provides a robust appeals process:

Internal Appeals

  • Timeline: 180 days from denial notice
  • Levels: Typically 1-2 internal review levels
  • Expedited Reviews: Available for urgent cases (≤72 hours for Medicare)

External Review Process

After exhausting internal appeals, you have 120 days to request external review through Virginia's Bureau of Insurance:

  1. Contact Bureau First: Call 1-877-310-6560 for guidance before submitting
  2. Complete Form 216-A: External Review Request form
  3. Submit Documentation: Include all denial letters, clinical records, and supporting evidence
  4. Independent Review: Bureau assigns case to qualified Independent Review Organization
  5. Decision Timeline: 45 days for standard review, 72 hours for expedited urgent cases

Virginia Bureau of Insurance Contact:

Virginia Advantage: The state allows expedited external review for cancer treatment denials without exhausting all internal appeals—a special provision reflecting Virginia's commitment to timely care access.

When navigating complex insurance approvals for specialty medications like Alecensa, having expert support can make the difference between approval and denial. Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned with each payer's specific requirements. Their platform helps patients, clinicians, and specialty pharmacies get prescription drugs approved by identifying the exact denial basis and crafting appeals with the right clinical evidence and procedural requirements.

FAQ

How long does UnitedHealthcare prior authorization take for Alecensa in Virginia? Standard prior authorization decisions are typically made within 72 hours for urgent requests and 15 days for non-urgent requests. Expedited reviews are available for time-sensitive cancer treatments.

What if Alecensa is not on my UnitedHealthcare formulary? You can request a formulary exception with supporting clinical documentation. Your oncologist must demonstrate medical necessity and why formulary alternatives are inappropriate.

Can I request an expedited appeal for Alecensa denial? Yes, if your physician certifies that waiting for standard review could seriously jeopardize your health. Expedited appeals in Virginia are decided within 72 hours.

Does step therapy apply if I've failed crizotinib outside Virginia? Yes, documented treatment failures from any location should satisfy step therapy requirements. Ensure your new Virginia provider has complete treatment records.

What happens if UnitedHealthcare denies my external review appeal? If Virginia's Independent Review Organization upholds the denial, you may still have legal options. Consider consulting with a healthcare attorney or patient advocacy organization.

How do I find UnitedHealthcare's approved specialty pharmacies for Alecensa? Contact UnitedHealthcare member services or check your provider portal for the current specialty pharmacy network. Common options include Accredo and OptumRx specialty pharmacies.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms, clinical circumstances, and current policies. Always consult with your healthcare provider and insurance plan for specific coverage determinations. For personalized assistance with complex appeals, consider working with specialized services like Counterforce Health that focus on insurance approval strategies for specialty medications.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.